CTLA4 and cancer: The lack of the significant synergistic or additive effect of the inhibitors added to the WBI clearly contrasts with the existing experimental and clinical evidence, indicating that the efficiency of cancer immunotherapy based on the blockade of CTLA-4 and/or PD-1 is enhanced when the blockade is combined with standard radiation therapy (reviewed in [19,29]).